Jagsonpal Pharmaceuticals Rewards Investors with ₹2.5 Dividend After Stellar Q4 Surge

Jagsonpal Pharmaceuticals Ltd. announced a dividend of ₹2.5 per equity share for the year ended March 31, 2025, following its robust Quarter 4 FY 2024-25 results announcement. The board's recommendation, a 125% payout on shares of a face value of ₹2, is a testament to the company's commitment to rewarding its shareholders in a period of robust financial performance.

 

The Q4 performance of the company demonstrates sustained momentum, underpinned by a year of robust growth and operational performance, with a Revenue from Operations pegged at 58.5 crores a whopping 35% jump Year-On-Year and the Net Profit for the company stood at 6.58 crores higher by 85% Year-On-Year. The recent quarters have witnessed Jagsonpal Pharmaceuticals delivering robust growth in revenue and profitability, with significant margin improvement in EBITDA and net profit. The strategic initiatives of the company, such as the successful integration of recent acquisitions and the divestment of its Faridabad facility, have also improved its balance sheet and operating profile.

 

On the stocks' front, Jagsonpal Pharmaceuticals' shares have performed better than its sector with a 7.26% rise on May 5, 2025, and posting a stupendous 75% return over the last year. The declaration of the dividend is also likely to add further strength to investors' confidence as the firm continues to reap opportunities for growth in the pharmaceuticals sector.

 

Source: Rediff Money